- Report
- May 2025
- 192 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- November 2024
- 120 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 310 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- April 2025
- 255 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- March 2025
- 451 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- December 2024
- 150 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- July 2024
- 150 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- May 2025
- 194 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 189 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 192 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- November 2024
- 323 Pages
Global
From €4478EUR$5,000USD£3,818GBP
- Report
- March 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- June 2025
- 72 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 93 Pages
Global
From €5240EUR$5,850USD£4,467GBP

The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used in clinical trials to evaluate the efficacy of new drugs.
PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment.
Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less Read more